Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540832 | 0.92 | MAPK14 (0.65) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2542314 | 0.91 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11HRH2 | |
| SCHEMBL12234642 | 0.90 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2542939 | 0.90 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2539682 | 0.89 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2546483 | 0.89 | MAPK14 (0.50) | MAPK14PPARG | |
| SCHEMBL2547456 | 0.89 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL14391398 | 0.88 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11HRH2 | |
| SCHEMBL12234636 | 0.85 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL18220828 | 0.83 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013175-B9 | p38 MAP KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2020-11-11 | — | — | EP | disclosed |
| US-8044211-B2 | P38 MAP kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-10-25 | — | — | US | disclosed |
| US-8044211-B2 | P38 MAP kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-10-25 | — | — | US | disclosed |
| US-8044211-B2 | P38 MAP kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-10-25 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099185-A1 | P38 Map Kinase Inhibitors | MAPK1, CNKSR1, MAPK3 | MAPK14 15/4885MAPK13 6/4885MAPK12 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.